Wyne P Lee Selected Research

Wyne P Lee Research Topics

Disease

20	Inflammation (Inflammations) 10/2022 - 06/2007
14	Asthma (Bronchial Asthma) 10/2022 - 12/2007
10	Neoplasms (Cancer) 01/2020 - 01/2005
6	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 06/2015
5	Arthritis (Polyarthritis) 01/2020 - 06/2007
5	Infections 01/2016 - 06/2010
4	Experimental Arthritis 01/2019 - 06/2007
4	Autoimmune Diseases (Autoimmune Disease) 06/2015 - 04/2004
3	Pneumonia (Pneumonitis) 11/2018 - 12/2013
3	Atrophy 08/2018 - 01/2018
3	Sepsis (Septicemia) 01/2018 - 07/2004
3	Choroidal Neovascularization 02/2016 - 03/2008
2	Pain (Aches) 01/2021 - 01/2021
2	Necrosis 11/2020 - 01/2018
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019 - 01/2017
2	Respiratory Hypersensitivity 11/2018 - 12/2015
2	Proteinuria 01/2017 - 01/2015
2	Rheumatoid Arthritis 12/2015 - 01/2011
2	Disease Progression 01/2015 - 06/2007
2	Human Influenza (Influenza) 07/2014 - 07/2013
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2010 - 04/2004
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2007 - 09/2005
2	Lymphoma (Lymphomas) 09/2005 - 01/2005
2	Shock 07/2004 - 07/2004
1	Eosinophilia 01/2022
1	Edema (Dropsy) 01/2021
1	Glomerulonephritis 01/2021
1	Cough 01/2021
1	Neuralgia (Stump Neuralgia) 01/2021
1	Autoimmune Lymphoproliferative Syndrome 11/2020
1	Bites and Stings (Sting) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Colitis 01/2020
1	Anaphylaxis (Anaphylactic Shock) 10/2019
1	Hereditary Neoplastic Syndromes (Cancer Syndrome, Hereditary) 01/2019

Drug/Important Bio-Agent (IBA)

10	CytokinesIBA 10/2022 - 01/2011
7	AntibodiesIBA 01/2016 - 12/2007
6	Phosphotransferases (Kinase)IBA 01/2020 - 12/2015
5	Proteins (Proteins, Gene)FDA Link 01/2017 - 04/2004
4	LipopolysaccharidesIBA 10/2015 - 07/2004
3	AllergensIBA 01/2022 - 12/2013
3	OvalbuminIBA 01/2021 - 12/2015
3	Immunoglobulin E (IgE)IBA 10/2019 - 06/2010
3	Interleukin-17 (Interleukin 17)IBA 01/2019 - 07/2009
3	Deubiquitinating EnzymesIBA 01/2019 - 12/2015
3	Interleukin-4 (Interleukin 4)IBA 11/2018 - 04/2004
3	Complement System Proteins (Complement)IBA 01/2018 - 06/2007
3	AntigensIBA 12/2015 - 04/2004
2	Biomarkers (Surrogate Marker)IBA 10/2022 - 10/2019
2	Peptide Hydrolases (Proteases)FDA Link 10/2022 - 12/2013
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 11/2018
2	LigandsIBA 01/2021 - 11/2020
2	Antigen-Antibody Complex (Immune Complex)IBA 01/2021 - 01/2017
2	AutoantibodiesIBA 01/2021 - 01/2011
2	Caspase 8 (Caspase-8)IBA 11/2020 - 01/2018
2	Tryptases (Tryptase)IBA 01/2020 - 10/2019
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020 - 04/2017
2	CollagenIBA 01/2020 - 01/2019
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 04/2017
2	Retinaldehyde (Retinal)IBA 08/2018 - 01/2018
2	CaspasesIBA 01/2018 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2018 - 10/2009
2	Interleukin-22 (IL-22)IBA 01/2017 - 10/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 03/2008
2	OX40 LigandIBA 01/2017 - 12/2007
2	UbiquitinIBA 04/2016 - 12/2015
2	Interferon-gamma (Interferon, gamma)IBA 07/2009 - 04/2004
2	dacetuzumabIBA 08/2006 - 09/2005
1	Kallikreins (Kallikrein)IBA 10/2022
1	PeriostinIBA 10/2022
1	Neutralizing AntibodiesIBA 10/2022
1	Hyaluronic Acid (Hyaluronan)IBA 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2022
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022
1	Fluticasone (Cutivate)FDA LinkGeneric 01/2022
1	SteroidsIBA 01/2022
1	tetrahydrofuranIBA 01/2021
1	Transient Receptor Potential ChannelsIBA 01/2021
1	compound 20IBA 01/2021
1	GDC-0334IBA 01/2021
1	SymportersIBA 01/2021
1	2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate (AITC)IBA 01/2021
1	Ion Channels (Ion Channel)IBA 01/2021
1	CalciumIBA 01/2021
1	AnkyrinsIBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Death Domain ReceptorsIBA 11/2020
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2020
1	sharpinIBA 01/2020
1	Interferon Type IIBA 01/2020
1	IgG Receptors (Fc gamma RI)IBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	c-Mer Tyrosine KinaseIBA 01/2020
1	Antigen Receptors (Antigen Receptor)IBA 01/2020
1	anti-IgE antibodiesIBA 10/2019
1	LaccaseIBA 01/2019

Therapy/Procedure

6	Therapeutics 01/2022 - 08/2006
2	Immunotherapy 01/2020 - 01/2005
2	Lasers (Laser) 08/2013 - 03/2008